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Role of Endothelial Shear Stress
in the Natural History of Coronary
Atherosclerosis and Vascular Remodeling
Molecular, Cellular, and Vascular Behavior
Yiannis S. Chatzizisis, MD, MSC,*† Ahmet Umit Coskun, PHD,‡ Michael Jonas, MD,†
Elazer R. Edelman, MD, PHD, FACC,*† Charles L. Feldman, SCD,* Peter H. Stone, MD, FACC*
Boston and Cambridge, Massachusetts
Although the entire coronary tree is exposed to the atherogenic effect of the systemic risk factors, atheroscle-
rotic lesions form at specific arterial regions, where low and oscillatory endothelial shear stress (ESS) occur. Low
ESS modulates endothelial gene expression through complex mechanoreception and mechanotransduction pro-
cesses, inducing an atherogenic endothelial phenotype and formation of an early atherosclerotic plaque. Each
early plaque exhibits an individual natural history of progression, regression, or stabilization, which is dependent
not only on the formation and progression of atherosclerosis but also on the vascular remodeling response. Al-
though the pathophysiologic mechanisms involved in the remodeling of the atherosclerotic wall are incompletely
understood, the dynamic interplay between local hemodynamic milieu, low ESS in particular, and the biology of
the wall is likely to be important. In this review, we explore the molecular, cellular, and vascular processes sup-
porting the role of low ESS in the natural history of coronary atherosclerosis and vascular remodeling and indi-
cate likely mechanisms concerning the different natural history trajectories of individual coronary lesions. Ath-
erosclerotic plaques associated with excessive expansive remodeling evolve to high-risk plaques, because low
ESS conditions persist, thereby promoting continued local lipid accumulation, inflammation, oxidative stress,
matrix breakdown, and eventually further plaque progression and excessive expansive remodeling. An enhanced
understanding of the pathobiologic processes responsible for atherosclerosis and vascular remodeling might
allow for early identification of a high-risk coronary plaque and thereby provide a rationale for innovative diag-
nostic and/or therapeutic strategies for the management of coronary patients and prevention of acute coronary
syndromes. (J Am Coll Cardiol 2007;49:2379–93) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.059s
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atherosclerosis is a chronic, inflammatory, fibroproliferative
isease primarily of large- and medium-sized conduit arter-
es (1,2). Although the entire vasculature is exposed to the
therogenic effects of the systemic risk factors (e.g., hyper-
ipidemia, cigarette smoking, hypertension, diabetes melli-
us, chronic infections, and genetic predisposition), athero-
clerotic lesions form at specific regions of the arterial tree,
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007, accepted February 26, 2007.uch as in the vicinity of branch points, the outer wall of
ifurcations, and the inner wall of curvatures, where dis-
urbed flow occurs (3). Local factors, such as hemodynamic
orces, play a major role in the regional localization of
therosclerosis (4–7). These local hemodynamic forces in-
lude flow-generated endothelial shear stress (ESS) and
lood pressure-derived tensile stress, with ESS playing the
ost fundamental role in atherosclerosis.
The first evidence implicating ESS in the localization
f atherosclerosis was described over 40 years ago by Caro
t al. (8). Later, sophisticated computational fluid dy-
amic simulations in autopsy-based models of coronary
rteries (9), carotid bifurcations (10), and distal abdom-
nal aortas (11) showed that areas with low ESS corre-
ated to the localization of atherosclerosis found at
utopsy. Further support of the atherogenic role of low
SS was also derived from in vivo experiments in animal
odels (12–14). In vivo investigations in humans, using
combination of intravascular ultrasound (IVUS) or
agnetic resonance imaging and computational fluid
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nistic role of low ESS in the
development and progression of
atherosclerosis (15–17). More
recent molecular and cellular
studies have begun to clarify the
detailed pathways by which low
ESS leads to atherosclerosis as
well as the development of thin
cap fibroatheromas, presumed or
suspected “vulnerable plaques,”
responsible for acute coronary
syndromes (18–22).
In addition to the processes of
atherosclerosis development and
progression, the local remodeling
characteristics of the arterial wall
in response to plaque growth
constitute crucial determinants
of the natural history and clinical
manifestations of an individual
atherosclerotic lesion. Local fac-
tors undoubtedly play an impor-
tant role in the nature of the
remodeling response as well
(5,15,22–25).
The purposes of this review
are to explore the molecular,
cellular, and vascular biologic
processes supporting the role of
low ESS in the natural history
f coronary atherosclerosis and vascular remodeling and
ndicate likely mechanisms concerning the different nat-
ral history trajectories of individual coronary lesions. An
nhanced understanding of the pathobiologic processes
esponsible for atherosclerosis and vascular remodeling
ight allow for early identification of a high-risk coro-
ary plaque and thereby provide a rationale for innovative
iagnostic and/or therapeutic strategies for the manage-
ent of coronary patients and prevention of acute coro-
ary syndromes.
efinitions of ESS and Blood Flow Patterns
ndothelial shear stress is the tangential stress derived from
he friction of the flowing blood on the endothelial surface
f the arterial wall and is expressed in units of force / unit
rea (N/m2 or Pascal [Pa] or dyne/cm2; 1 N/m2  1 Pa 
0 dyne/cm2) (26,27) (Table 1). Endothelial shear stress is
roportional to the product of the blood viscosity () and
he spatial gradient of blood velocity at the wall (ESS 
 dv/dy) (Fig. 1).
The nature of fluid flow through a tube is dependent on
he velocity of flow and the presence of geometric irregu-
arities or obstructions. Fluid flow might be either laminar
Abbreviations
and Acronyms
EC  endothelial cell
ECM  extracellular matrix
eNOS  endothelial nitric
oxide synthase
ESS  endothelial shear
stress
IEL  internal elastic
lamina
IL  interleukin
LDL  low-density
lipoprotein cholesterol
MAPK  mitogen-activated
protein kinase
MMP  matrix
metalloproteinase
NF-B  nuclear factor-
kappa B
NO  nitric oxide
ROS  reactive oxygen
species
SREBP  sterol regulatory
elements binding protein
TCFA  thin cap
fibroatheroma
TF  transcription factor
VSMC  vascular smooth
muscle cellr turbulent (26,28) (Fig. 2). Laminar flow refers to aerminology of Arterial Hemodynamics
Table 1 Terminology of Arterial Hemodynamics
Term Definition
Endothelial shear stress (ESS) The tangential force derived by the friction
of the flowing blood on the endothelial
surface. It is the product of the shear rate
at the wall and the blood viscosity ().
Shear rate The spatial gradient of blood velocity, which
describes how fast the blood velocity
increases from areas at the arterial wall
toward areas at the center of the lumen
(i.e., dv/dy, where dv is change in flow
velocity unit and dy is change in unit of
radial distance from the wall).
Physiologically, the shear rate decreases
at the center of the lumen and gradually
increases toward the wall.
Blood viscosity A principal property of blood related to its
internal friction that causes blood to
resist flow. Hematocrit is the major
determinant of blood viscosity.
Newtonian blood behavior Constant blood viscosity independent of
shear rate. In large-sized arteries (e.g.,
aorta) blood behaves largely in a
Newtonian fashion.
Non-Newtonian blood behavior Non-constant blood viscosity inversely
related to shear rate. Blood has non-
Newtonian properties, especially in veins,
small-sized arteries, and in the
microcirculation.
Laminar flow Smooth, streamlined blood flow where
viscous forces prevail against inertial
forces.
Undisturbed laminar blood flow Smooth streamlined flow characterized by
concentric layers of blood moving in
parallel along the course of the artery.
The highest velocity is found at the centre
of the lumen, whereas the lowest velocity
occurs along the wall. Uniform laminar
blood flow primarily occurs in relatively
straight arterial segments.
Disturbed laminar blood flow Disturbed laminar flow characterized by
reversed flow (i.e., flow separation,
recirculation, and reattachment to
forward flow). Disturbed laminar blood
flow occurs in arterial segments with
geometric irregularities (e.g., curvatures,
branches, bifurcations), or upstream and
downstream of stenoses.
Turbulent blood flow Flow in which the blood velocity at any given
point varies continuously over time, even
though the overall flow is steady. In
turbulent flow the inertial forces are more
significant than viscous forces. Turbulent
blood flow rarely occurs but has been
described in human aorta at peak
systole, during heavy exercise in much of
the central arterial system, distal to
severe stenoses (75%), and in
aneurysms.
Reynolds number (Re) The ratio of blood inertial forces to viscous
forces. For a given geometry, whether the
flow will be laminar or turbulent is
determined by its Reynolds number. For
low Re values blood flow is laminar,
whereas for high Re values (typically,
above 2,000) blood flow is turbulent.
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June 26, 2007:2379–93 Shear Stress, Atherosclerosis, and Remodelingtreamlined flow and can be further divided into undis-
urbed laminar flow, characterized by smooth streamlines
Fig. 2A), and disturbed laminar flow, characterized by areas
ith reversed flow (i.e., flow separation, recirculation, and
eattachment to forward flow) or circumferential swirling
26,29) (Fig. 2B). In turbulent flow the velocity at any given
oint varies continuously over time, even though the overall
ow is steady (Fig. 2C). For a given geometry, whether the
ow will be laminar or turbulent is determined by its
eynolds number (Re); for low Re values, flow is laminar,
hereas for high Re values (typically, above 2,000), flow is
urbulent (7,26,30).
The pulsatile (unsteady) nature of the arterial blood flow
n combination with the complex geometric configuration of
he coronaries determines the ESS patterns, which are
haracterized by direction and magnitude (10,31,32). In
Figure 1 Definition of ESS
Endothelial shear stress (ESS) is proportional to the product of the blood
viscosity () and the spatial gradient of blood velocity at the wall (dv/dy).
ontinued
Table 1 Continued
Term Definition
Steady blood flow Blood flow in which velocity does not vary
with time. This type of flow does not
occur in vivo; however, it has been largely
used in computational fluid dynamic
studies.
Pulsatile (unsteady) blood flow Blood flow with periodically changing
velocity during the cardiac cycle.
Steady ESS ESS that does not vary with time (i.e.,
constant direction and magnitude).
Pulsatile ESS Unidirectional ESS with a magnitude varying,
typically, within a range of 15 to 70
dyne/cm2 over the cardiac cycle, yielding
a positive time-average.
Low ESS Unidirectional ESS with a periodically varying
magnitude over the cardiac cycle, yielding
a significantly low time-average (10 to
12 dyne/cm2).
Oscillatory ESS Bidirectional ESS with a periodically varying
magnitude over the cardiac cycle, yielding a
very low time-average, usually close to 0.
ESS spatial gradient ESS variations over short distances. High
ESS spatial gradients occur primarily in
geometrically irregular arterial regions.elatively straight arterial segments, ESS is pulsatile and
nidirectional with a magnitude that varies within a range of
5 to 70 dyne/cm2 over the cardiac cycle and yields a
ositive time-average (4–6) (Fig. 3). In contrast, in geo-
etrically irregular regions, where disturbed laminar flow
ccurs, pulsatile flow generates low and/or oscillatory ESS.
Figure 2 Characteristics of Flow Patterns
Schematic figure illustrating the characteristics of flow patterns. (A) Undis-
turbed laminar flow is a smooth streamlined flow chacterized by concentric lay-
ers of blood moving in parallel along the course of the artery; (B) disturbed
laminar flow is characterized by reversed flow (i.e., flow separation, recircula-
tion, and reattachment to forward flow); (C) in turbulent flow the blood velocity
at any given point varies continuously over time, even though the overall flow is
steady. Adapted from Munson et al. (28). Re  Reynolds number.
Figure 3 Definition and Example of
Pulsatile, Low, and Oscillatory ESS
Definition of pulsatile, low, and oscillatory
endothelial shear stress (ESS). Adapted from Ku et al. (10).
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Shear Stress, Atherosclerosis, and Remodeling June 26, 2007:2379–93ow ESS refers to ESS that is unidirectional at any given
oint but has a periodically fluctuating magnitude that
esults in a significantly low time-average (approximately
10 to 12 dyne/cm2) (4,6,15) (Fig. 3). However, the
bsolute threshold effect of low ESS is likely dependent on
oncomitant conditions, such as systemic factors, or inter-
pecies differences (33). Low ESS typically occurs at the
nner areas of curvatures as well as upstream of stenoses
34). Oscillatory ESS is characterized by significant changes
n both direction (bidirectional) and magnitude between
ystole and diastole, resulting in a very low time-average,
sually close to 0 (4–6) (Fig. 3). Oscillatory ESS occurs
rimarily downstream of stenoses, at the lateral walls of
ifurcations, and in the vicinity of branch points
6,10,34,35). Beside the temporal oscillations, ESS experi-
nces significant spatial oscillations over short distances,
specially in geometrically irregular regions, resulting in
igh spatial gradients, which are also involved in athero-
clerosis (14,35–37).
Although low ESS and oscillatory ESS are closely
ssociated with atherogenesis, the relative importance of
hese different ESS patterns is unclear. In a mouse carotid
rtery in vivo model, both low ESS and oscillatory ESS
Figure 4 Endothelial Mechanotransduction of ESS
Local endothelial shear stress (ESS) is sensed by luminal endothelial mechanorec
kinase receptors (TKRs), nicotinamide adenine dinucleotide phosphate (NADPH) ox
proteoglycans. Also, ESS signals are transmitted through the cytoskeleton to the b
complex consisting of platelet endothelial cell adhesion molecule-1 (PECAM-1) and
vated integrins phosphorylate and activate a multiple complex of non-receptor tyro
guanine nucleotide exchange factors (Sos, C3G), thereby activating Ras family GTP
triggers various parallel downstream cascades of serine kinases; each of these ki
vating mitogen-activated protein kinases (MAPKs). Besides integrin-mediated mech
tiated by luminal or junctional mechanoreceptors. These pathways include the pro
protein kinase C (PKC), activation of Rho family small GTPases (which mediate the
ECs), release of endothelial nitric oxide synthase (eNOS) and other signaling mole
Ultimately, all of these signaling pathways lead to phosphorylation of several trans
(AP-1). These TF proteins bind positive or negative shear stress responsive eleme
expression, thereby modulating cellular function and morphology.ed to atherosclerotic plaque formation, but only low, conoscillatory ESS was associated with inflammatory
hanges and proclivity to rupture (21). Different vascular
erritories (e.g., femoral, carotid, and coronary arteries)
ight also respond differently to various ESS stimuli
33). The magnitude of local low ESS is critically
ssociated with the severity of atherosclerotic plaque
haracteristics (19).
SS Mechanoreception,
ignal Transduction, and
echanosensitive Gene Expression
ndothelial cell (EC) surfaces (luminal, junctional, and
asal) are equipped with numerous mechanoreceptors capa-
le of detecting and responding to ESS stimuli (38–40)
Fig. 4). After activation of mechanoreceptors, a complex
etwork of several intracellular pathways is triggered, a
rocess known as mechanotransduction (38,39,41– 45)
Fig. 4). These pathways are activated simultaneously and
ross-talk with each other; the great majority of them
onverge into the mitogen-activated protein kinase
MAPKs) cascade at various levels, suggesting the key role
f MAPKs in ESS mechanotransduction (39). Cytoskeleton
, such as ion channels (K, Ca2, Na, Cl), G-proteins, caveolae, tyrosine
and xanthine oxidase (XO), plasma membrane lipid bilayer, and heparan sulfate
r junctional endothelial surface, where certain integrins or a mechanosensory
are activated, respectively, and initiate a downstream signaling cascade. Acti-
nases (FAK, c-Src, Shc, paxillin, and p130CAS), adaptor proteins (Grb2, Crk), and
ctive Ras plays a pivotal role in intracellular transduction of ESS signals as it
phosphorylates and hence activates the next one downstream, ultimately acti-
nsduction, ESS activates a number of other downstream signaling pathways ini-
of reactive oxygen species (ROS) from NADPH oxidase and XO, activation of
deling cytoskeleton resulting in temporary or permanent structural changes of
from caveolae, and activation of phosphoinositide-3 kinase (PI3K)-Akt cascade.
n factors (TFs), such as nuclear factor-kappa  (NF-B) and activator protein-1
REs) at promoters of mechanosensitive genes inducing or suppressing theireptors
idase
asal o
Flk-1
sine ki
ase. A
nases
anotra
duction
remo
cules
criptio
nts (SSonstitutes a central mediator in ESS signaling by providing
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June 26, 2007:2379–93 Shear Stress, Atherosclerosis, and Remodelingscaffold for the formation or translocation of various
ignaling molecules, serving as a bond between the luminal
urface, where ESS is imposed, and several luminal, basal, or
unctional formations, where the signaling pathways initiate
45) (Fig. 5). These pathways lead to phosphorylation of
everal transcription factors (TFs), which bind positive or
egative shear stress responsive elements (SSREs) at pro-
oters of mechanosensitive genes, inducing or suppressing
heir expression and, ultimately, modulating cellular func-
ion and morphology (4,6,46–48). In arterial regions with
on-disturbed flow, where ESS varies within a physiologic
ange, the ECs express various atheroprotective genes and
uppress several pro-atherogenic ones, leading eventually to
tability and quiescence in that region (6,48). In contrast, in
egions with low and disturbed flow where low ESS occurs,
he atheroprotective genes are suppressed, whereas the
ro-atherogenic genes are upregulated, thereby promoting
he atherosclerotic process (6,48).
ole of Low ESS in Atherosclerosis
ow ESS attenuates nitric oxide (NO)-dependent
theroprotection. Nitric oxide, a key component of normal
ascular tone, also possesses strong anti-inflammatory, anti-
poptotic, anti-mitogenic, and anti-thrombotic properties
49) (Table 2). Physiologic pulsatile ESS constitutes the
ost potent stimulus for continuous NO production by the
ndothelium, an effect that is regulated at either transcrip-
ional level through upregulation of endothelial nitric oxide
ynthase (eNOS) gene expression (50) or at post-
ranscriptional level by eNOS protein phosphorylation and
ctivation (51). In arterial regions with disturbed flow, low
SS reduces the bioavailability of NO by decreasing eNOS
essenger ribonucleic acid (mRNA) and protein expression,
hereby exposing the endothelium to the atherogenic effect
Figure 5 Role of Cytoskeleton in ESS Mechanotransduction
The endothelial cytoskeleton transmits the shear forces to the focal adhesions loc
cade starts. The shear forces can also be transmitted to mechanoreceptors at the
ESS  endothelial shear stress.f local and systemic risk factors (12,13,49,52,53) (Fig. 6). (n addition, low ESS downregulates prostacyclin, another
ndothelial vasodilatory substance (4,53), while upregulat-
ng endothelin-1 (ET-1) (4,52,53), a potent vasoconstric-
ive and mitogenic molecule, thereby precipitating
therosclerosis.
ow ESS promotes low-density lipoprotein cholesterol
LDL) uptake, synthesis, and permeability. Low ESS
auses a sustained endothelial activation of sterol regulatory
lements binding proteins (SREBPs), a family of endoplas-
ic reticulum-bound TFs that upregulate the expression of
enes encoding LDL receptor, cholesterol synthase, and
atty acid synthase (54) (Fig. 6). In the context of systemic
yperlipidemia, this effect results in an increased engage-
ent and synthesis of LDL by the ECs, ultimately promot-
ng the subendothelial accumulation of LDL (55). Acti-
ated SREBPs also appear to induce interleukin (IL)-8 and,
oncomitantly, monocyte accumulation into the intima,
uggesting an additional role of these TFs in the local
nflammatory processes (56).
In addition to active SREBPs-dependent LDL uptake
nd synthesis, disturbed flow increases the permeability of
he endothelial surface to LDL (14,38,57) (Fig. 6). The
egulation of cell cycle and survival by shear forces might
lay an important role in increasing LDL permeability.
ighly mitotic and apoptotic activity of ECs was found in
egions susceptible to atherosclerosis, where low and oscil-
atory ESS occur (58,59). The accentuated ECs mitosis and
poptosis as well as the conformational changes of ECs
rom fusiform to polygonal shape associated with low ESS
ight be responsible for the widening of the junctions
etween ECs (4,55,60). These small “gaps” between ECs, in
ombination with flow stagnation and the subsequent pro-
ongation of the residence time of circulating LDL, facili-
ate the infiltration of LDL underneath the endothelium
t the basal endothelial surface, where a downstream intracellular signaling cas-
cell junctions, luminal surface, and nucleus (N). Adapted from Davies et al. (45).ated a
cell–6,29).
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Shear Stress, Atherosclerosis, and Remodeling June 26, 2007:2379–93ow ESS promotes oxidative stress. Once LDL particles
re engulfed in the subendothelial layer, they are associated
ith intimal proteoglycans, become entrapped, and undergo
xidative modification (1,2). Low ESS promotes production
f reactive oxygen species (ROS) into the intima and,
ventually, oxidation of LDL, by enhancing gene expression
nd post-transcriptional activity of the major oxidative
nzymes (nicotinamide adenine dinucleotide phosphate
NADPH] oxidase and xanthine oxidase) at EC mem-
ranes (49,61,62) (Fig. 6). Low ESS appears also to
ownregulate the intracellular ROS scavengers, such as
anganese superoxide dismutase and glutathione, further
ugmenting local oxidative stress (47,63). Generated ROS
egrade NO and its co-factors (e.g., tetrahydrobiopterin),
educing the bioavailability of atheroprotective NO and
urther enhancing the production of ROS (e.g., superoxide
O2
] or peroxynitrite [ONOO]) (49).
ow ESS promotes inflammation. The recruitment of
irculating inflammatory cells (monocytes, T-lymphocytes,
ast cells, eosinophils, dendritic cells) into the intima to
cavenge oxidized LDL constitutes a major pathogenetic
omponent in the atherosclerotic process (64). Low ESS
lays a key role in the localized attachment and infiltration
f these cells into the arterial wall through activation of
ertain TFs, notably nuclear factor-kappa  (NF-B), and
ubsequent translocation to the nucleus (36,65–67) (Fig. 6).
ctivation of NF-B is further promoted by low shear-
nduced oxidative stress (61). In addition, a negative feed-
ack mechanism occurs between NF-B and NO, in that
educed eNOS expression and subsequent NO production
ccurring in low ESS regions increases the activity of
F-B (67).
Various endothelial genes are upregulated downstream
o low shear-induced NF-B activation. These include
enes that encode several adhesion molecules, such as
ontinued
Table 2 Continued
Effect of Low ESS
Plaque calcification
BMP-4 Upregulated
Plaque thrombogenecity
eNOS/NO Downregulated
Prostacyclin Downregulated
Thrombomodulin No effect (38,104)
t-PA Downregulated (38,105)
Blood stagnation— accumulation of
blood thrombogenic factors
close to the wall
Increased (6,29)
CE  angiotensin-converting enzyme; bFGF  basic fibroblast growth factor; BMP  bone
orphogenic protein; EC  endothelial cell; eNOS/NO  endothelial nitric oxide synthase/nitric
xide; ESS  endothelial shear stress; ET  endothelin; ICAM  intercellular adhesion molecule;
FN  interferon; IL  interleukin; LDL  low-density lipoprotein cholesterol; MCP  monocyte
hemoattractant protein; MMP  matrix metalloproteinase; Mn SOD  manganese-dependant
uperoxide dismutase; NADPH  nicotinamide adenine dinucleotide phosphate; PAI  plasmino-
en activator inhibitor; PDGF  platelet derived growth factor; TGF  transforming growth factor;
NF tumor necrosis factor; t-PA tissue plasminogen activator; VCAM vascular cell adhesion
olecule; VEGF  vascular endothelial growth factor; VSMC  vascular smooth muscle cell.ndothelial Genes and Vascularunc ions Regulated by Low ESS in Atherosclerosis
Table 2 Endothelial Genes and VascularFunctions Regulated by Low ESS in Atherosclerosis
Effect of Low ESS
Impaired flow-dependent vasodilation
Vasodilators
eNOS/NO Downregulated (4,12,13,52,53)
Prostacyclin Downregulated (4,53)
Vasoconstrictors
ET-1 Upregulated (4,52,53)
Subendothelial accumulation of LDL
Endothelial LDL uptake and synthesis Increased (54)
Endothelial LDL permeability Increased (14,57)
Blood stagnation—accumulation of
LDL close to the wall
Increased (6,29)
ECs proliferation and apoptosis Increased (58,59)
Oxidative stress
Oxidative enzymes
NADPH oxidase Upregulated (61)
Xanthine oxidase Upregulated (62)
Antioxidative enzymes
Mn SOD Downregulated (47)
Glutathione Downregulated (63)
Inflammation
Chemoattractants (MCP-1) Upregulated (46,47,66)
Adhesion molecules (VCAM-1,
ICAM-1, E-selectin)
Upregulated (21,46,47,65-68)
Cytokines (TNF-, IL-1, IFN-) Upregulated (46,47)
BMP-4 Upregulated (7,101)
Leukocyte pseudopod projection Increased (69)
Blood stagnation—accumulation of
monocytes close to the wall
Increased (6,29,68)
VSMCs migration, differentiation, and
proliferation
Growth promoters
PDGF-A, PDGF-B Upregulated (4,70)
ET-1 Upregulated
VEGF Upregulated (21,71)
bFGF Unclear (4,73)
ACE Unclear (4,38)
Angiotensin II Unclear (38,73)
Growth inhibitors
eNOS/NO Downregulated
TGF- Downregulated (4,74,75)
PAI-1 Downregulated (22,72)
Regulation of extracellular matrix
content and composition
Increased matrix degradation
MMP-2, MMP-9 Upregulated (21,22,80-82)
Cathepsin L Upregulated (93)
Reduced matrix synthesis
IFN- Upregulated
VSMCs apoptosis Increased
eNOS/NO Downregulated
TGF- Downregulated
Neovascularization
VEGF Upregulated
Other angiogenic factors
(e.g., angiopoietin-2)
Upregulated (46)ascular cell adhesion molecule (VCAM)-1; intercellular
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June 26, 2007:2379–93 Shear Stress, Atherosclerosis, and Remodelingdhesion molecule (ICAM)-1 and E-selectin; chemoat-
ractant chemokines, such as monocyte chemoattractant
rotein (MCP)-1; and pro-inflammatory cytokines, such
s tumor necrosis factor (TNF)-, interleukin (IL)-1,
nd interferon (IFN)- (21,46,47,65– 68). Adhesion
olecules are expressed on EC surface and mediate the
olling and adhesion of circulating leukocytes on the
ndothelial surface, whereas MCP-1 promotes transmi-
ration of leukocytes, particularly monocytes, into the
ntima. The intimal infiltration of inflammatory cells
ppears also to be mechanistically facilitated by blood
ow stagnation and endothelial junction widening, pri-
arily occurring in areas with disturbed flow (6,29,68)
Fig. 6). Low ESS might also provoke pseudopod pro-
ection through mechanotransduction processes and
inding of leukocytes on the endothelium (69). Once
onocytes infiltrate underneath the endothelium they
ndergo structural and functional alterations and differ-
ntiate to macrophages, which sustain the inflammation,
xidative stress, and dynamic matrix remodeling, thereby
romoting atherosclerosis progression (1,2,64).
ow ESS promotes vascular smooth muscle cell (VSMC)
igration, differentiation, and proliferation. Low ESS
romotes endothelial gene and protein expression of potent
SMC mitogens, such as platelet-derived growth factor
PDGF)-A and -B isoforms (4,70), ET-1 (4,52,53), and
ascular endothelial growth factor (VEGF) (21,71) (Fig. 6).
Figure 6 Role of Low ESS in Atherosclerosis
In arterial regions with disturbed laminar flow, low endothelial shear stress (ESS) s
thereby promoting atherogenesis, atherosclerotic plaque formation and progressio
 intercellular adhesion molecule; IFN  interferon; IL  interleukin; LDL  low-de
matrix metalloproteinase; NO  nitric oxide; PDGF  platelet-derived growth factor
transforming growth factor; TNF  tumor necrosis factor; t-PA  tissue plasminoge
growth factor; VSMC  vascular smooth muscle cell; other abbreviations as in Figow ESS-induced formation of ROS and pro-inflammatory cytokines also promote the expression of these growth
actors (1). Also, low and disturbed flow decreases the
ndothelial expression of plasminogen activator inhibitor
PAI)-1, an inhibitor of VSMC migration (22,72). Al-
hough the effect of low ESS on basic fibroblast growth
actor (bFGF), angiotensin converting enzyme (ACE), and
ngiotensin II is yet unclear (4,38,73), potent suppressors of
ell growth and migration, such as NO (52) and transform-
ng growth factor (TGF)- (4,74,75) are downregulated in
reas with low and disturbed flow (Fig. 6). Ultimately, low
SS-mediated over-expression of growth promoters and
nder-expression of growth inhibitors by the ECs stimulate
SMCs to migrate from media to intima through a region-
lly disrupted internal elastic lamina (IEL) (76,77). Within
he intima VSMCs acquire a “synthetic” phenotype, pro-
ucing collagen and other extracellular matrix (ECM)
roteins, and proliferate (1). Over time, VSMCs along with
he fibroblasts create a fibrous cap around the lipid core
solating the thrombogenic lipid material from the circulat-
ng platelets. The fibrous cap along with the lipid core
onstitute the so-called early atherosclerotic plaque (fibrous
ap atheroma; American Heart Association type IV lesion)
78,79).
ow ESS promotes ECM degradation in vascular wall
nd plaque fibrous cap. The ECM of vascular wall and
brous cap is composed of a complex mixture of collagen
nd elastin fibers within a ground substance of proteogly-
he endothelial function and structure toward an atherosclerotic phenotype,
vascular remodeling. BMP  bone morphogenic protein; ET  endothelin; ICAM
lipoprotein cholesterol; MCP  monocyte chemoattractant protein; MMP 
P  sterol regulatory elements binding protein; TF  transcription factor; TGF 
vator; VCAM  vascular cell adhesion molecule; VEGF  vascular endothelialhifts t
n, and
nsity
; SREB
n acti
ure 4.ans and glycosaminoglycans. In vitro and in vivo animal
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Shear Stress, Atherosclerosis, and Remodeling June 26, 2007:2379–93xperiments have demonstrated that low ESS upregulates
ene expression and activity of matrix metalloproteinases
MMPs), particularly MMP-2 (or gelatinase-A) and9 (or
elatinase-B) (21,22,80–82), which are the major proteases
ssociated with ECM degradation in the atherosclerotic
laques (83– 86) (Fig. 6). Pro-inflammatory cytokines
TNF-, IL-1, IFN-) comprise the major stimuli for the
elease of MMPs from their key cellular sources (ECs,
acrophages, VSMCs, T-lymphocytes, and mast cells) via
he MAPKs pathway and subsequent activation of TFs
e.g., NF-B and activator protein [AP]-1) (86–88). Low
SS increases MMPs expression by ECs through activation
f these TFs. Moreover, low ESS enhances the accumula-
ion of macrophages and VSMCs within the plaque, where
he upregulated pro-inflammatory cytokines stimulate them
o secrete MMPs. Reactive oxygen species, which are
entral effectors in low ESS signaling, also enhance the
xpression and activity of MMPs (86).
Whereas MMPs are the matrix degrading endopeptidases
hat have been most extensively investigated, several other
roteases have been shown to play a key role in matrix
reakdown, including cysteine proteases (e.g., cathepsins S,
, L) (89–92), serine proteases (e.g., tissue plasminogen
ctivator [t-PA], urokinase-plasminogen activator [u-PA],
lasmin) (87), and mast cells-derived chymase and tryptase
64,87). Low ESS upregulates the expression of cathepsin L
y ECs, macrophages, and VSMCs, probably through an
F-B–dependent and cytokine-dependent pathway simi-
ar to that of MMPs (93) (Fig. 6).
ow ESS attenuates ECM synthesis in vascular wall and
laque fibrous cap. In addition to intensive ECM degra-
ation, low and disturbed flow attenuates ECM synthesis.
nterferon-, a pro-inflammatory cytokine derived by the
ctivated T-lymphocytes in response to low ESS, consti-
utes a potent inhibitor of collagen synthesis by VSMCs
94,95) and simultaneously promotes Fas-related VSMC
poptosis (96). Vascular smooth muscle cell apoptosis can
e also induced by low shear-generated oxidative stress
hrough activation of Fas signaling pathways (97). Next to
heir role in VSMC turnover, TGF- and NO constitute
otent inducers of collagen synthesis by VSMCs as well as
nti-inflammatory molecules (49,74). Downregulated endo-
helial expression of TGF- and eNOS genes due to low
SS might contribute to increased inflammation and re-
uced matrix synthesis (98) (Fig. 6).
otential role of low ESS in plaque neovascularization.
eovascularization (angiogenesis) constitutes a key factor in
he progression and vulnerability of atherosclerotic plaques
y supplying them with lipoproteins, inflammatory cells,
atrix proteases, and ROS (99). Low ESS indirectly pro-
otes intimal neovascularization by inducing intimal thick-
ning and thus ischemia, upregulating the expression of
EGF (21,71) and other angiogenic factors (e.g.,
ngiopoietin-2) (46), enhancing local inflammation, oxida-
ive stress, and expression of matrix degrading enzymes and lccentuating EC and VSMC migration and proliferation
100) (Fig. 6).
otential role of low ESS in plaque calcification. Bone
orphogenic protein (BMP)-4, a member of the TGF-
uperfamily of cytokines (74), has recently been shown to be
pregulated in ECs exposed to low and oscillatory ESS
7,101) (Fig. 6). The BMP-4 stimulates the expression and
ctivity of NADPH oxidase, thereby leading to ROS
roduction, NF-B activation, pro-inflammatory cytokine
xpression, and subsequent increased monocyte adhesivity
f ECs. In addition, BMP-4 participates in plaque calcifi-
ation, suggesting a potential role of low ESS in the
ormation of spotty deposits of calcium at the base of the
laque, close to the IEL, surrounded by inflammatory cells
19,102,103).
ow ESS increases plaque thrombogenecity. Low ESS
ncreases plaque thrombogenecity by downregulating the
xpression of eNOS and prostacyclin, well known for their
nti-thrombotic properties (52,53) (Fig. 6). Furthermore,
ow ESS exerts no effect on thrombomodulin, a major
nticoagulant of endothelial surface, which is physiologically
pregulated by laminar flow (38,104), whereas it decreases
he expression of t-PA, thereby promoting thrombosis
38,105) (Fig. 6). Blood stagnation occurring at areas with
isturbed flow might also facilitate the accumulation of
lood thrombogenic factors (e.g., platelets) close to the wall
29). All these thrombogenic actions might be detrimental
n the setting of an acute fibrous cap disruption, contribut-
ng to abrupt thrombus formation and, therefore, manifes-
ation of an acute coronary syndrome.
ole of Low ESS in
therosclerotic Wall Remodeling
he nature and clinical significance of an atherosclerotic
laque is dependent not only on the formation and progres-
ion of atherosclerosis but also on the vascular remodeling
esponse to that atherosclerosis (106,107). A controlled and
elf-limited physiologic process of matrix protein synthesis
nd breakdown maintains the integrity of the arterial wall.
he key mediators of this balance are the matrix-producing
ells, primarily VSMCs and fibroblasts, and the matrix-
egrading proteases, primarily MMPs and cathepsins
86,91). The function of VSMCs is regulated by a dynamic
quilibrium between growth-promoting (e.g., PDGF,
T-1, VEGF, angiotensin II) and growth-inhibiting mol-
cules (e.g., TGF-, NO, IFN-). Similarly, the activity of
MPs and cathepsins is regulated by a balance between
heir synthesis and post-transcriptional activation and inhi-
ition by their inhibitors (e.g., tissue inhibitors of matrix
etalloproteinases [TIMPs], cystatin C for cathepsins)
86,91). Although the pathophysiologic mechanisms in-
olved in the remodeling of the atherosclerotic wall are
ncompletely understood, the dynamic interplay between
ocal hemodynamic milieu and the biology of the wall is
ikely to be important (23,86).
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June 26, 2007:2379–93 Shear Stress, Atherosclerosis, and Remodelingxpansive remodeling. Expansive (or outward) remodel-
ng, the process of arterial enlargement in response to local
therosclerotic plaque formation or hemodynamic distur-
ance, was initially described in primates (108). Glagov
t al. (109) was the first to demonstrate in human coronary
rteries that the presence of atherosclerotic plaque within
he arterial wall leads to vessel enlargement so that the
umen remains preserved (i.e., compensatory expansive
emodeling). More recent studies indicated that although
pproximately 60% of atherosclerotic coronary arteries
ith minor luminal stenosis exhibit compensatory expan-
ive remodeling, approximately 20% exhibit excessive
xpansive remodeling, such that both vessel and lumen
re actually larger than the neighboring, non-involved
Figure 7 Proposed Natural History of Coronary Atherosclerosis
The initiating process of atherosclerosis in an atherosclerosis-prone host is a low
atheroma, which might be diffuse. The vascular response to that early fibroatherom
there is local compensatory expansive remodeling, then the local ESS is normalize
lesion evolves to a quiescent plaque with limited inflammation. However, in the pr
undergo excessive expansive remodeling. In this context the local low ESS environ
petuating vicious cycle is established among local low ESS, excessive expansive r
fibroatheroma. The stenotic plaques might either evolve with a phenotype promotin
end-stage of scarring in the setting of prior inflamed thin cap fibroatheroma throug
undergo local erosion or develop calcified nodules and lead to local thrombus form
the figure are based on intravascular ultrasound studies (23,110,111).reas (23,110,111) (Fig. 7). (Although in normal arteries, low ESS elicits an adap-
ive response of the arterial wall leading to constrictive
emodeling and, consequently, an increase in ESS to
hysiologic levels, in atherosclerotic arteries the response
o low ESS is very complex (15,21,23,24,112). Low ESS
eads to the development of focal plaque and, in the
etting of a continued low ESS environment, the wall
eneath the plaque becomes inflamed and acquires the
nzymatic products that shift the ECM balance toward
egradation. Within such an environment IEL undergoes
evere fragmentation, and the atherosclerotic process
xtends into the media degrading the collagen and elas-
in fibers, thereby promoting arterial expansion and ac-
ommodation of the enlarging plaque (20 –22,86,113)
elial shear stress (ESS) environment, leading to the formation of an early fibro-
ly determines the nature of the subsequent natural history of that plaque. If
hemodynamic stimulus for further plaque progression is resolved, and the early
of certain local, systemic, and genetic factors, the local vascular wall might
persists, promoting further plaque progression and vessel expansion. A self-per-
ling, and plaque inflammation, transforming the early fibroatheroma to a thin cap
proliferation consistently throughout their natural history course or represent an
titive microruptures and healing. Also, the stenotic plaques might infrequently
and manifestation of an acute coronary syndrome. The percentages reported inendoth
a like
d, the
esence
ment
emode
g fibro
h repe
ationFig. 7).
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Shear Stress, Atherosclerosis, and Remodeling June 26, 2007:2379–93It is currently unknown what factors determine whether
he expansive remodeling response to atherosclerosis be-
omes either compensatory or excessive. Recent observa-
ions, however, indicate that low ESS leads to excessive
xpansive remodeling and, furthermore, that the severity of
EL degradation and excessive expansive remodeling is
ignificantly associated with the magnitude of low ESS (20).
n the setting of very low ESS, local lipid accumulation,
nflammation, and oxidative stress are enhanced, thereby
romoting intensive ECM degradation, culminating in
xcessive vascular wall expansion, which perpetuates or
xacerbates the local low ESS environment (19,20) (Fig. 7).
ystemic factors (e.g., magnitude of hyperlipidemia, hyper-
lycemia, hypertension) and genetic factors might also
nterplay with the low ESS microenvironment and modu-
ate the excessive expansion of the arterial wall (19,20).
onstrictive remodeling. When fibroproliferative pro-
esses predominate against inflammation and subsequent
atrix breakdown, the atherosclerotic wall undergoes con-
trictive or inward remodeling, leading to luminal narrowing
114). Approximately 20% of even minimally diseased
uman coronary arteries exhibit constrictive remodeling,
uggesting that vascular constriction might occur as a direct
esponse to plaque growth (23,110,115,116) (Fig. 7). His-
opathology data showed that constrictive remodeling might
lso occur as a stage in the evolution of high-risk plaques
hrough processes of wound healing in response to repetitive
laque microruptures (117,118) (Fig. 7). Studies indicate
lso that lipid-lowering treatment with statins enhances
broproliferative processes leading to constrictive remodel-
ng (119). Low ESS does not appear to play a direct role in
he pathobiology of constrictive remodeling.
ole of Low ESS
n the Differential Development
f Early Fibroatheroma Into High-Risk,
uiescent, or Stenotic Atherosclerotic Plaque
he classification of individual atherosclerotic lesions has been
n issue of substantial and ongoing debate concerning histo-
ogic characteristics and functional correlates. The first system-
tic classification was reported by Stary et al. (78) and later
odified by Virmani et al. (79). In this review we use a
implified classification scheme of atherosclerotic plaques
ased on discrete histomorphologic, functional, and clinical
haracteristics (i.e., histopathology, progression rate, associated
ascular remodeling pattern, degree of vulnerability, and re-
ated clinical outcome): 1) high-risk plaques; 2) quiescent
laques; and 3) stenotic plaques (Table 3). High-risk plaques
re typically thin cap fibroatheromas (TCFAs) in 60% to 70%
f cases, characterized by a thin, inflamed fibrous cap and a
arge necrotic lipid core, rich in neovessels (79,120,121) (Fig.
). These high-risk plaques are usually minimally stenotic
esions associated with expansive vascular remodeling and an
ncreased risk of sudden rupture and precipitation of an acute
oronary syndrome (106,107,122–125). Quiescent plaques are aon-stenotic or minimally stenotic lesions with a thick fibrous
ap and a small lipid core (Fig. 7). These plaques remain
iologically quiescent and thus cause no symptoms (30).
inally, stenotic plaques are stable fibroproliferative lesions
ith modest inflammation, characterized morphologically by a
elatively thick, collagen-rich fibrous cap, overlying a small
ipid core (79,124,126) (Fig. 7). These lesions are associated
ith constrictive vascular remodeling and over time might
ecome occlusive, resulting in chronic stable angina
106,107,115,122).
Although atherosclerosis is a systemic and diffuse disease, its
anifestations are multi-focal, given that plaques of each of the
forementioned types co-exist in the same patient, indeed even
n the same artery, at a single point in time (127,128). Local
actors, such as low ESS and local remodeling response, are
ikely critical determinants of the subsequent natural history of
ach individual atherosclerotic plaque (15,18,129).
evelopment of high-risk plaques (TCFAs). There have
een very limited serial investigations of the progression of
arly atherosclerotic plaque to determine the natural history of
ach plaque and the determinants responsible for the course of
hat natural history. A recent study using serial IVUS and
mmunohistochemical analyses in a diabetic atherosclerotic pig
odel found that low ESS was an independent predictor of
laque location, development, and progression to a high-risk
laque with intensive lipid accumulation, inflammation, thin
brous cap, IEL fragmentation, media thinning, and excessive
xpansive remodeling (18–20) (Fig. 7). Furthermore, the
agnitude of low ESS at baseline was significantly associated
ith the severity of high-risk plaque characteristics in follow-
p. Intriguingly, in areas of low ESS where high-risk plaque
eveloped, excessive expansive remodeling occurred, associated
ith persistence of a low ESS environment despite continued
laque growth, thereby fostering a vicious cycle among low
SS, excessive expansive remodeling, and high-risk plaque
haracteristics (19,20) (Fig. 7).
evelopment of quiescent plaques. The hemodynamic or
orphologic characteristics promoting plaque quiescence are
ot well understood. A recent serial IVUS and histopathology
atural history study demonstrated that those local coronary
rterial subsegments that developed only minimal or interme-
iate atherosclerotic plaque after prolonged follow-up were
hose areas with either physiologic or slightly low ESS at
aseline (18–20). These areas primarily developed compensa-
ory and not excessive, expansive remodeling and did not
cquire the high-risk characteristics of plaque progression, lipid
ccumulation, inflammation, and IEL degradation compared
ith areas with lower ESS at baseline (Fig. 7). Furthermore,
he ESS after long-term follow-up in these areas with only
inimal or intermediate plaque was virtually the same as at
aseline, suggesting there was little ongoing stimulus for
xacerbation of plaque progression and arterial expansion (20).
owever, the long-term stability or quiescence of these plaques
s unknown. If local vascular conditions later change, such that
low ESS microenvironment is recreated or the systemictherosclerotic stimulus is enhanced, then the process of
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June 26, 2007:2379–93 Shear Stress, Atherosclerosis, and Remodelingrogressive atherosclerosis, inflammation, and vascular remod-
ling might again re-emerge.
evelopment of stenotic (fibrous) plaques. Stenotic le-
ions either evolve with a phenotype promoting fibroprolifera-
ion consistently throughout its natural history course (115) or
epresent an end-stage of scarring in the setting of prior
epetitive microruptures of an inflamed TCFA (117) (Fig. 7).
he local hemodynamic or morphologic factors responsible for
n early plaque to evolve into a fibrous plaque are unknown.
he magnitude of local ESS stimuli for cellular proliferation/
brosis versus inflammation might play a decisive role in
etermining whether the balance between ECM degradation
nd synthesis favors less inflammation and more ECM syn-
hesis (i.e., development of stenotic plaque) or favors ECM
egradation (i.e., development of TCFA) (130) (Fig. 7).
Stenotic plaques infrequently undergo local erosion or de-
elop calcified nodules, which might lead to local thrombus
ormation and manifestation of an acute coronary syndrome
20% to 40% of cases) (79). Low ESS does not appear to play
role in the pathophysiology of plaque erosion. However, high
SS, which occurs at the neck of highly stenotic plaques,
ight be responsible for the local endothelial erosion and
nduction of acute coronary thrombosis (31) (Fig. 7).
linical Implications of Assessing ESS
ecause ruptured TCFAs account for the great majority of the
cute coronary syndromes, early understanding of the degree of
isk associated with an individual plaque and the identification
f plaques at risk to evolve to TCFAs is anticipated to have
onsiderable clinical impact. Although systemic therapy is the
oundation to reduce risk in patients with coronary disease,
ystemic strategies alone might be insufficient to adequately
ddress the high-risk patient or the high-risk coronary lesion.
he PROVE-IT–TIMI-22 (Pravastatin or Atorvastatin Eval-
ation and Infection Therapy–Thrombolysis in Myocardial
nfarction-22) trial, for example, indicated that although very
ggressive systemic therapy (i.e., atorvastatin 80 mg q.d.)
educed the primary end point of death or a major cardiovas-
ular event by 16% compared with standard statin therapy (i.e.,
ravastatin 40 mg q.d.) after a mean follow up of 24 months,
primary end point event nevertheless still occurred in 22.4%
f the intensive treatment group (131). Clearly an incremental
pproach beyond systemic therapy would be of value in the
lassification Scheme for the Natural History of Early Atherosclero
Table 3 Classification Scheme for the Natural History of Early A
Plaque Trajectory Histopathology Progression Rate
Quiescent plaque Small lipid core
Thick fibrous cap
Minimal C
Stenotic plaque Small lipid core
Very thick fibrous
cap
Gradual C
High-risk plaque Large lipid core
Thin and
inflamed fibrous
cap
Increased Eanagement of these high-risk patients. A focused strategy of ddentification of an early stage of a high-risk lesion might be
omplementary to systemic therapy by enabling a highly
elective local intervention to avert a future acute coronary
vent (103).
Several in vivo technologies for the assessment of the
unctional and morphologic characteristics of a particular
laque now exist, including multislice computed tomography,
agnetic resonance imaging, position emission tomography,
VUS-based virtual histology and palpography, thermography,
ptical coherence tomography, near-infrared spectroscopy, in-
ravascular magnetic resonance imaging, and angioscopy (103).
lthough these modalities might be useful to characterize a
articular plaque, they might be insufficient to optimally
redict future risk, because they provide a snapshot of the
laque at only a single point in time. Thus, these modalities are
ost useful to identify only the ends of the spectrum between
stenotic plaque and a high-risk plaque, but they cannot
ddress the stimuli responsible for the subsequent natural
istory of that plaque. Incorporation of an in vivo assessment of
ocal ESS stimuli and local remodeling behavior of a particular
laque might substantially enhance the prognostic significance
f these imaging modalities, because one can then have insight
oth into the existing nature and the future natural history of
hat plaque (15,23,25).
The most comprehensive technique for investigating the
elationship between ESS and vascular pathobiology is a
ethodology known as “vascular profiling,” which uses routine
VUS and coronary angiography to create an accurate
-dimensional representation of the coronary artery, and this
orms the basis of identifying both local ESS and vascular
emodeling behavior (5,15) (Fig. 8). Vascular profiling is
ccurate (132–134) and highly reproducible (135) and can be
sed to track changes in lumen, wall thickness, and ESS in
eriods as short as 6 to 9 months in human (15,23) or in
xperimental animals (18,19). Future technologies might be
ble to non-invasively assess local ESS and remodeling behav-
or with multi-slice computed tomography, magnetic reso-
ance imaging, or other imaging approaches (17). A natural
istory clinical study of atherosclerotic plaques using vascular
rofiling techniques in patients with coronary artery disease is
ow underway (PREDICTION [Prediction of Progression of
oronary Artery Disease and Clinical Outcome Using Vascu-
ar Profiling of Shear Stress and Wall Morphology] trial) to
aques (Early Fibroatheromas)
osclerotic Plaques (Early Fibroatheromas)
ular Remodeling Proclivity to Rupture Clinical Manifestation
nsatory expansive
odeling
Low Asymptomatic
ctive remodeling Low Stable angina
ve expansive
odeling
High Acute coronary syndrometic Pl
ther
Vasc
ompe
rem
onstri
xcessi
remetermine the incremental value of characterizing the local
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Shear Stress, Atherosclerosis, and Remodeling June 26, 2007:2379–93SS and remodeling environment to predict the development
f new acute cardiac events.
In vivo understanding of the local hemodynamic environ-
ent responsible for individual plaque behavior and natural
istory, in combination with molecular imaging and the
nformation provided by systemic biomarkers of vulnerability,
ight allow for detailed risk stratification of individual early
oronary plaques (5,19,103). Identification of a high-risk
laque in its early stages of development might provide a
ationale for highly selective, prophylactic local coronary inter-
entions (e.g., implantation of stents), supplemented by an
ntensive systemic pharmacologic approach, to avert a future
cute coronary event (15,103,136). The clinical and economic
mplications of identifying and treating individual high-risk
oronary lesions are anticipated to be enormous.
onclusions
ow ESS is a powerful local stimulus for atherogenesis,
ormation, and progression of an early atherosclerotic plaque
nd differentiation to high-risk plaque. Variations in the local
ntravascular hemodynamic environment over time lead to
ynamic interactions with the arterial wall that might either
xacerbate or ameliorate the progression of an early plaque. An
n vivo understanding of plaque characteristics, local ESS, and
ascular remodeling response might lead to an enhanced
Figure 8 Example of Vascular Profiling With Reconstructed Hum
(A) Example of a 3-dimensional (3D) reconstructed coronary arterial segment. (B)
(ESS) profiling along a 3D reconstructed left anterior descending artery. Panel A wnderstanding of the pathobiology of coronary artery diseasend provide opportunities for highly selective pre-emptive local
nterventions.
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